Investigational Site Number :1580002

Tainan 704

0 studies enrolling now · 9 studies all time

What they study most

Breast Cancer, Breast Cancer Metastatic, Chronic Kidney Diseases, Gastric Cancer, Heart Failure, Lung Neoplasm Malignant, Malignant Solid Tumor, Metastatic Neoplasm, Neoplasm, Neoplasm Malignant, Non-small Cell Lung Cancer, Pancreatic Carcinoma Metastatic

Studies at this site

• A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) — Stopped early
• Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors — Stopped early
• Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors — Stopped early
• Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer — Stopped early
• Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies — Stopped early
• A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors — Completed
• Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies — Stopped early
• Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk — Stopped early
• Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies — Stopped early